{"id":"dorzolamide-timolol-and-latanoprost","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation/burning"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eyelash growth/darkening"},{"rate":null,"effect":"Iris pigmentation changes"},{"rate":null,"effect":"Systemic beta-blocker effects (bradycardia, fatigue)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dorzolamide and timolol work synergistically on aqueous humor production while latanoprost enhances drainage through the uveoscleral pathway. This triple mechanism provides additive intraocular pressure reduction compared to individual agents. The combination is designed for patients with glaucoma or ocular hypertension requiring multi-drug therapy.","oneSentence":"This combination reduces intraocular pressure through three mechanisms: dorzolamide inhibits carbonic anhydrase to decrease aqueous humor production, timolol blocks beta-adrenergic receptors to reduce aqueous humor secretion, and latanoprost increases uveoscleral outflow of aqueous humor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:30.946Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06369077","phase":"PHASE4","title":"How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?","status":"TERMINATED","sponsor":"CT Glaucoma Associates","startDate":"2024-04-22","conditions":"Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":36},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT00572936","phase":"PHASE2","title":"Circadian Rhythms of Aqueous Humor Dynamics in Humans","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-03-13","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT00140049","phase":"PHASE4","title":"A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":238},{"nctId":"NCT00397241","phase":"PHASE4","title":"24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-09","conditions":"Open-angle Glaucoma","enrollment":33},{"nctId":"NCT02802137","phase":"PHASE4","title":"24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2015-03","conditions":"Glaucoma, Ocular Surface Disease","enrollment":43},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02522039","phase":"NA","title":"Pupillary Response After Glaucoma Medication","status":"COMPLETED","sponsor":"Glostrup University Hospital, Copenhagen","startDate":"2014-05","conditions":"Drug Effect (Glaucoma Drugs)","enrollment":21},{"nctId":"NCT01175902","phase":"NA","title":"Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2011-03","conditions":"Normal Tension Glaucoma","enrollment":44},{"nctId":"NCT01887223","phase":"PHASE2","title":"Transconjunctival Needling Revision Versus Medical Treatment","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2010-05","conditions":"Primary Open Angle Glaucoma","enrollment":40},{"nctId":"NCT00815373","phase":"NA","title":"The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG)","status":"WITHDRAWN","sponsor":"Meir Medical Center","startDate":"2008-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01304264","phase":"","title":"Intraocular Pressure, Blood Pressure, Ocular Perfusion and Blood Flow Fluctuations in Glaucoma Patients","status":"COMPLETED","sponsor":"Lithuanian University of Health Sciences","startDate":"2011-03","conditions":"Open Angle Glaucoma","enrollment":35},{"nctId":"NCT00796198","phase":"PHASE4","title":"Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2008-12","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT00440336","phase":"NA","title":"Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.","status":"UNKNOWN","sponsor":"Advanced Glaucoma Specialists","startDate":"2006-10","conditions":"Open Angle Glaucoma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eliptic Ofteno PF®","Gaap Ofteno PF®"],"phase":"marketed","status":"active","brandName":"Dorzolamide-timolol and latanoprost","genericName":"Dorzolamide-timolol and latanoprost","companyName":"Laboratorios Sophia S.A de C.V.","companyId":"laboratorios-sophia-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces intraocular pressure through three mechanisms: dorzolamide inhibits carbonic anhydrase to decrease aqueous humor production, timolol blocks beta-adrenergic receptors to reduce aqueous humor secretion, and latanoprost increases uveoscleral outflow of aqueous humor. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}